Patients suffering from a rare form of cancer known as advanced gastrointestinal neuroendocrine tumors (NETs) previously had limited options when it came to treatment. On top of this, very few oncologists are trained, or specialized in this type of tumor treatment, making a patient’s prospects of receiving the help they need even less promising. But this may soon change. A research team from The European Cancer Organization (ECCO) has just completed the third phase of their randomized, international trial using a new treatment for NETs.
So far, they are astounded by their results, finding that patients who have mid-gut NETs and receive this treatment live longer without the disease getting worse. Their findings will be reported on Saturday at the 2015 European Cancer Congress. A diagnosis of mid-gut NETs does not happen frequently. According to the study, about five in every 100,000…
